Yale Liver Center
Yale Liver Center
批准号:
10388648
负责人:
MICHAEL H NATHANSON
金额:
$5.07万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-03-18 至 2022-02-28
关键词:
Adenovirus InfectionsAffectAmericanAnimal ModelAwardBasic ScienceBile fluidCRISPR/Cas technologyCell Culture TechniquesCell LineCell SeparationCell modelCellsClinical ResearchCollaborationsCore FacilityDiagnosisDigestive System DisordersDisciplineDiseaseDoctor of PhilosophyEndothelial CellsEquipmentEquus caballusEtiologyExperimental ModelsFibroblastsGene ExpressionHepaticHepatocyteHumanHuman ResourcesKnowledgeLiverLiver diseasesLymphocyteMissionMolecularMusOrganoidsPhysiologyPreparationProceduresPublic HealthQuality ControlRattusRecording of previous eventsReproducibilityResearchResearch PersonnelResourcesReverse Transcriptase Polymerase Chain ReactionServicesSmall Interfering RNASupervisionTechnical ExpertiseTissuesTransfectionTranslational ResearchUniversitiesWorkcell preparationcholangiocytecostcost effectiveexperienceimaging detectioninduced pluripotent stem cellinnovationprotein expressionresearch facilitystellate cell
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY – CELLULAR MOLECULAR PHYSIOLOGY CORE
The Cellular and Molecular Physiology Core is the “work horse” of this Center, but it also continues to serve as
an innovation hub to provide liver investigators with the most up-to-date experimental models. The core is
organized to provide technical expertise, equipment and personnel to Liver Center Investigators in order to
provide them with state of the art cell and molecular research resources in an efficient, quality-controlled and
cost-effective manner. The Core has a long history of developing new cell and animal models for liver research.
Currently, the Core is divided into two Components: (1) The Cell Isolation and Cell Culture Component and (2)
The Molecular Component. These are subdivided into: (a) Isolated cell preparations, including: hepatocytes,
cholangiocytes, endothelial cells, stellate cells, portal fibroblasts and hepatic lymphocytes, primarily from mice
and rats. Human hepatocytes are also utilized when available. Over 3,400 separate cell isolations were
performed during the current award period; (b) Cell culture facilities for short and long-term cultures and cell
lines; (c) Protein and gene expression using Quantitative RT-PCR and Infrared imaging detection; (d) Altering
gene expression in liver-related cells, cell lines and tissues using siRNA transfection, adenovirus infection, and
CRISPR technologies; (e) providing a variety of animal models of liver disease and (f) disease-specific mouse
and human liver organoids, derived from iPSC’s, bile, and primary liver tissue. By centralizing these procedures
in a Core facility, cost and effort are dramatically reduced, investigators are assured of a high degree of rigor,
reproducibility, and quality control, and preparations can often be used simultaneously by more than one
investigator. Mario Strazzabosco, MD, PhD, who has more than 25 years of relevant experience, directs this
core with the collaboration of the Emeritus Director, James L. Boyer, MD, who has more than 4 decades of
experience working with these preparations and procedures. They are assisted by Romina Fiorotto, PhD, and
Shi-Ying Cai, PhD, which assures daily supervision, availability, and advice to investigators for many of these
services.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Interactions between neutrophils and cholangiocytes in alcoholic hepatitis
-
批准号:10298412
-
项目类别:
-
资助金额:$65.79万
-
财政年份:2021
-
负责人:MICHAEL H NATHANSON
-
依托单位:
Interactions between neutrophils and cholangiocytes in alcoholic hepatitis
-
批准号:10494268
-
项目类别:
-
资助金额:$65.8万
-
财政年份:2021
-
负责人:MICHAEL H NATHANSON
-
依托单位:
Interactions between neutrophils and cholangiocytes in alcoholic hepatitis
-
批准号:10617893
-
项目类别:
-
资助金额:$16.75万
-
财政年份:2021
-
负责人:MICHAEL H NATHANSON
-
依托单位:
Interactions between neutrophils and cholangiocytes in alcoholic hepatitis
-
批准号:10646369
-
项目类别:
-
资助金额:$64.88万
-
财政年份:2021
-
负责人:MICHAEL H NATHANSON
-
依托单位:
Interactions between neutrophils and cholangiocytes in alcoholic hepatitis
-
批准号:10874892
-
项目类别:
-
资助金额:$16.75万
-
财政年份:2021
-
负责人:MICHAEL H NATHANSON
-
依托单位:
Ca2+ waves in hepatocytes: Mechanisms and effects
-
批准号:10388244
-
项目类别:
-
资助金额:$51.46万
-
财政年份:2018
-
负责人:MICHAEL H NATHANSON
-
依托单位:
Ca2+ waves in hepatocytes: Mechanisms and effects
-
批准号:9902430
-
项目类别:
-
资助金额:$51.46万
-
财政年份:2018
-
负责人:MICHAEL H NATHANSON
-
依托单位:
Molecular regulation of cholestasis in cholangiocytes
-
批准号:9925220
-
项目类别:
-
资助金额:$47.89万
-
财政年份:2018
-
负责人:MICHAEL H NATHANSON
-
依托单位:
Enrichment Program
-
批准号:8916082
-
项目类别:
-
资助金额:$59.01万
-
财政年份:2015
-
负责人:MICHAEL H NATHANSON
-
依托单位:
Trafficking of the EGF receptor to the nucleus: Mechanisms and Effects
-
批准号:8152910
-
项目类别:
-
资助金额:$7.7万
-
财政年份:2012
-
负责人:MICHAEL H NATHANSON
-
依托单位:
Trafficking of the EGF receptor to the nucleus: Mechanisms and Effects
-
批准号:8490515
-
项目类别:
-
资助金额:$7.59万
-
财政年份:2012
-
负责人:MICHAEL H NATHANSON
-
依托单位:
Trafficking of the EGF receptor to the nucleus: Mechanisms and Effects
-
批准号:8607221
-
项目类别:
-
资助金额:$7.75万
-
财政年份:2012
-
负责人:MICHAEL H NATHANSON
-
依托单位:
A laser scanning confocal microscope for research and education
-
批准号:7838072
-
项目类别:
-
资助金额:$93.12万
-
财政年份:2010
-
负责人:MICHAEL H NATHANSON
-
依托单位:
A confocal endomicroscope for clinical research
-
批准号:7791136
-
项目类别:
-
资助金额:$15.99万
-
财政年份:2010
-
负责人:MICHAEL H NATHANSON
-
依托单位:
Regulation of Liver by Nuclear Ca2+ Signaling
-
批准号:7861351
-
项目类别:
-
资助金额:$2.36万
-
财政年份:2009
-
负责人:MICHAEL H NATHANSON
-
依托单位:
Ca2+ Waves in Hepatocytes: Mechanisms and Effects
-
批准号:7905575
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2009
-
负责人:MICHAEL H NATHANSON
-
依托单位:
Morphology Core
-
批准号:7688377
-
项目类别:
-
资助金额:$23.5万
-
财政年份:2009
-
负责人:MICHAEL H NATHANSON
-
依托单位:
CELL IMAGING
-
批准号:7424053
-
项目类别:
-
资助金额:$11.78万
-
财政年份:2007
-
负责人:MICHAEL H NATHANSON
-
依托单位:
Core--Administrative
-
批准号:7500426
-
项目类别:
-
资助金额:$15.54万
-
财政年份:2007
-
负责人:MICHAEL H NATHANSON
-
依托单位:
REGULATION OF CELL GROWTH BY NUCLEAR CALCIUM
-
批准号:7424049
-
项目类别:
-
资助金额:$22.57万
-
财政年份:2007
-
负责人:MICHAEL H NATHANSON
-
依托单位:
海外基金